Literature DB >> 10817811

Atherosclerosis--an autoimmune disease.

G Wick1, Q Xu.   

Abstract

Immune-inflammatory processes are increasingly discussed as possible pathogenetic factors involved in the development of atherosclerosis. Here, we summarize data on which we have built our "immunological" hypothesis of atherogenesis. This concept is based on the observation that nearly everybody shows protective cellular and humoral immune reactions against microbial heat shock protein 60 (HSP 60). Because a high degree of antigenic homology exists between microbial (viral, bacterial, parasitic) and human HSP 60, this protective immunity may have to be "paid for" by the danger of cross-reactivity with human HSP 60 that is expressed by endothelial cells of stressed arteries. Arterial endothelial cells are more prone to produce HSP 60 and various adhesion molecules upon exposure to stress factors, including classical risk factors for atherosclerosis, due to their life-long exposure to the high arterial as compared to venous blood pressure. Also, endothelial cells are the first potential targets encountered by circulating HSP 60-specific T cells or antibodies. This concept not only opens new avenues for diagnostic approaches, but also may form the basis for new ways of therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10817811

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  12 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Diet-induced elevation of circulating HSP70 may trigger cell adhesion and promote the development of atherosclerosis in rats.

Authors:  Fang Xie; Rui Zhan; Li-Cheng Yan; Jing-Bo Gong; Yun Zhao; Jing Ma; Ling-Jia Qian
Journal:  Cell Stress Chaperones       Date:  2016-07-19       Impact factor: 3.667

3.  Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements.

Authors:  A G Pockley; J Frostegård
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

Review 4.  Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe?

Authors:  Tangchun Wu; Robert M Tanguay
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 5.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 6.  Vaccination to modulate atherosclerosis.

Authors:  Takayuki Kimura; Kevin Tse; Alessandro Sette; Klaus Ley
Journal:  Autoimmunity       Date:  2015-02-16       Impact factor: 2.815

7.  Comparison of epitope specificity of anti-heat shock protein 60/65 IgG type antibodies in the sera of healthy subjects, patients with coronary heart disease and inflammatory bowel disease.

Authors:  George Füst; Katalin Uray; László Bene; Ferenc Hudecz; István Karádi; Zoltán Prohászka
Journal:  Cell Stress Chaperones       Date:  2011-10-29       Impact factor: 3.667

Review 8.  Exosomes in atherosclerosis: Convergence on macrophages.

Authors:  Kaiying Yang; Qi Xiao; Mengying Niu; Xudong Pan; Xiaoyan Zhu
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

9.  Progression of arteriovenous bypass restenosis in mice exposed to a 50 Hz magnetic field.

Authors:  Blair Henderson; Andrea Tagwerker; Christina Mayrl; Gerald Pfister; Günther Boeck; Hanno Ulmer; Hermann Dietrich; Georg Wick
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

10.  Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.

Authors:  Priscila Camillo Teixeira; Axel Ducret; Philippe Ferber; Hubert Gaertner; Oliver Hartley; Sabrina Pagano; Michelle Butterfield; Hanno Langen; Nicolas Vuilleumier; Paul Cutler
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.